Skip to main content
OpenTrials
Completed

NCT Number: NCT02522468

A Trial of RSL Versus WL for Malignant Breast Disease

The purpose of this randomized trial is to determine the superiority of utilizing radioactive seed localization (RSL) over wire-guided localization (WL) for palpable or non-palpable malignant lesions in patients undergoing breast conservation surgery (BCS).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–99 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Levine Cancer Institute

Charlotte, North Carolina, 28204, United States

About this study

Consented and eligible subjects will be randomized to either radioactive seed localization or wire localization and stratified by surgeon and invasive versus DCIS prior to localization. Subjects on both arms will undergo breast conservation surgery including surgical specimen removal. Specimens will be grossed according to standard of care procedures. Localization, breast conservation surgery, and post-operative appointments will follow standard of care guidelines. Surveys will be administered according to the study calendar to the radiologist, surgeon, pathologist, and subject for data collection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female
  • 20 to 99 years of age
  • Breast lesion necessitating image-guided excision
  • Unifocal disease
  • Breast-conservation candidate
  • Biopsy-proven malignant breast lesion including by not limited to invasive ductal carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ
  • Signed written informed consent document by the subject and/or a LAR

Exclusion criteria

  • Male
  • Multifocal or multicentric disease
  • Receiving neoadjuvant chemotherapy
  • Pregnant or breastfeeding
  • Locally advanced disease
  • Breast conservation contraindication such as inability to receive whole breast radiation therapy, inability to tolerate localization procedure, inability to lay flat or prone for radiation, and undesirable tumor to breast ratio
  • Prior breast cancer on ipsilateral side
  • Unable or unwilling to adhere to post-localization instructions (e.g. timely seed removal)

Treatment and study plan

Radioactive Seed Localization

Procedure

Wire Localization

Procedure

Primary outcomes

  1. Surgical Resection Margins

    Time frame: 30 days

    The primary objective for this study will be the comparison between Radioactive Seed Localization (RSL) and Wire-Guided Localization (WL) based on negative margins in malignant breast disease. This is defined as no tumor on ink in invasive disease and greater than or equal to 2mm from the inked margin in non-invasive disease (DCIS).

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Registry information

Official study title

A Randomized Single-Center Superiority Trial of Radioactive Seed Localization Versus Needle Localization for Malignant Breast Disease.

Acronym: BCS-RSL-001

Important dates

Study start
2015
Primary completion
2021
Study completion
2021
First posted
Aug 13, 2015
Registry last updated
Aug 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.